Abstract
The use of nanocarriers as drug delivery systems for chemotherapeutic agents can improve the overall pharmacological properties of commonly used drugs in chemotherapy. The clinical success, as well as the ease with which surface modifi cations can be made to both liposomes and micelles to accommodate targeting ligands have made these nanocarriers in particular attractive candidates for future work involving targeted drug delivery. Although not targeted, there are clinically approved liposomal-based drugs that are currently used to treat various types of cancers. Furthermore, there are several other formulations involving both of these nanocarriers which are now in various stages of clinical trials. This review discusses the use of liposomes and micelles in cancer therapy and attempts to provide some current information regarding the clinical status of several of these nanocarrier-based drugs. In addition, recent work involving the incorporation of targeting ligands to systems such as these in order to improve colocalization between the drug and cancer cells is also addressed. Furthermore, while the use of these nanocarriers in particular is the primary focus here, this review also contains a discussion on other commonly used nanocarriers in cancer therapy to include various polymer-based and polymer-protein conjugates. Finally, the possibility of using combinatorial approaches involving multiple surface modifi cations made to both liposomes and micelles in order to further improve their drug delivery capabilities is also discussed.
Highlights
Cancer treatment involving chemotherapy is typically accompanied by toxic side effects, thereby limiting the amount of the drug that can be given to a patient
The clinical success based on passively delivering chemotherapeutics encapsulated within both liposomes and micelles in cancer treatment have made these nanocarriers attractive candidates for future work involving a more active form of delivery
This type of targeted drug delivery improves the colocalization between the drug and cancer cells based on modifications made to the nanocarrier thereby avoiding direct conjugation between the drug and targeting ligand, and many potentially successful constructs have been reported here
Summary
Cancer treatment involving chemotherapy is typically accompanied by toxic side effects, thereby limiting the amount of the drug that can be given to a patient. While the use of both liposomes and micelles in cancer therapy seems promising, obstacles associated with drug transfer from these nanocarriers to tumor cells within the tumor site remain challenging. This review discusses the use of both liposomes and micelles as nanocarriers for chemotherapeutics, and some current information regarding the clinical status of various drugs encapsulated within both of these drug delivery systems is provided.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.